Systematic review confirms GI side effects are common with all obesity drugs, especially GLP-1 agonists during dose escalation | Research

The takeaway

Systematic review of 12 studies (including 18,386-participant cohort) confirms nausea, vomiting, diarrhea, and constipation are most common with GLP-1 drugs during dose escalation, while orlistat causes steatorrhea and phentermine reduces GI motility.

GLP-1 GI effects peak during titration
Nausea, vomiting, diarrhea, and constipation are most common during GLP-1 drug dose escalation—tailored titration and proactive counseling can improve tolerability

What the researchers found

GLP-1RAs: nausea, vomiting, diarrhea, constipation (worst during dose escalation). Orlistat: steatorrhea, flatulence. Phentermine: ↓GI motility. Retatrutide, orforglipron: notable GI profiles. Natural products: fewer AEs but limited data. Generally mild-moderate but affect adherence.

Why it matters

GI side effects are the #1 reason patients stop obesity medications. Understanding the specific profile of each drug class enables better counseling and management strategies.

How the study worked

PRISMA 2020 systematic review. PubMed, Google Scholar, BMJ, Web of Science (to July 2025). 12 studies. Cochrane RoB 2 and Newcastle-Ottawa quality assessment.

What this study cannot tell us

Heterogeneous study designs. Inconsistent AE reporting. Most data from clinical trials. Long-term GI outcomes unknown for newer agents.

How to read the evidence

Systematic review of 12 studies. Good methodology but limited by heterogeneous reporting.

When this study was published

Published in 2025; literature through July 2025.

The bigger picture

As the obesity drug landscape expands from 2 to 10+ agents, comparative GI safety data becomes essential for drug selection. This review provides the first systematic comparison in non-diabetic populations.

Questions still open

Which dose escalation protocol minimizes GI side effects?
Could proactive anti-nausea therapy improve GLP-1 drug adherence?
Do GI side effects attenuate with long-term use?

Common questions

Do all weight loss drugs cause stomach problems?

Most do, but in different ways. GLP-1 drugs (semaglutide, tirzepatide) mainly cause nausea and vomiting, especially when doses increase. Orlistat causes oily stool and gas from fat malabsorption. Phentermine slows gut motility. The good news: most side effects are mild to moderate and often improve with time and gradual dose titration.

How can GI side effects be minimized on GLP-1 drugs?

Slow dose escalation is key—following recommended titration schedules rather than jumping to higher doses. Eating smaller meals, avoiding high-fat foods, and proactive anti-nausea medication can help. Most patients find symptoms improve after the first few weeks at each dose level.

Read the original research

Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review.

Medicina (Kaunas, Lithuania), 61(11)

View on PubMed ↗Publisher’s paper ↗

Citation

Takrori, Ehab; Peshin, Supriya; Singal, Sakshi. (2025). Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review.. Medicina (Kaunas, Lithuania), 61(11). https://doi.org/10.3390/medicina61111987